Tumor evolution and chemoresistance in ovarian cancer

被引：137

作者：

Kim, Soochi ^{[1
,2
]}

Han, Youngjin ^{[2
,3
]}

Kim, Se Ik ^{[4
]}

Kim, Hee-Seung ^{[4
]}

Kim, Seong Jin ^{[5
,6
]}

Song, Yong Sang ^{[2
,3
,4
,7
]}

机构：

[1] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul 03080, South Korea

[2] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul 03080, South Korea

[3] Seoul Natl Univ, WCU Biomodulat, Dept Agr Biotechnol, Seoul 03080, South Korea

[4] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul 03080, South Korea

[5] Seoul Natl Univ, Precis Med Res Ctr, Adv Inst Convergence Technol, Suwon 16229, Gyeonggi Do, South Korea

[6] Seoul Natl Univ, Dept Transdisciplinary Studies, Grad Sch Convergence Sci & Technol, Suwon 16229, Gyeonggi Do, South Korea

[7] Seoul Natl Univ, Interdisciplinary Program Canc Biol, Coll Med, Seoul 03080, South Korea

来源：

NPJ PRECISION ONCOLOGY | 2018年 / 2卷

关键词：

CLEAR-CELL CARCINOMA; GRADE SEROUS CARCINOMA; NEOADJUVANT CHEMOTHERAPY; CLONAL EVOLUTION; FALLOPIAN-TUBE; INTRAEPITHELIAL CARCINOMA; INTRATUMOR HETEROGENEITY; 1ST-LINE CHEMOTHERAPY; PROGNOSTIC NOMOGRAM; HISTONE DEMETHYLASE;

D O I：

10.1038/s41698-018-0063-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Development of novel strategies to overcome chemoresistance is central goal in ovarian cancer research. Natural history of the cancer development and progression is being reconstructed by genomic datasets to understand the evolutionary pattern and direction. Recent studies suggest that intra-tumor heterogeneity (ITH) is the main cause of treatment failure by chemoresistance in many types of cancers including ovarian cancer. ITH increases the fitness of tumor to adapt to incompatible microenvironment. Understanding ITH in relation to the evolutionary pattern may result in the development of the innovative approach based on individual variability in the genetic, environment, and life style. Thus, we can reach the new big stage conquering the cancer. In this review, we will discuss the recent advances in understanding ovarian cancer biology through the use of next generation sequencing (NGS) and highlight areas of recent progress to improve precision medicine in ovarian cancer.

引用

页数：9

共 117 条

[1] Predicting biomarkers for ovarian cancer using gene-expression microarrays [J].

Adib, TR ;

Henderson, S ;

Perrett, C ;

Hewitt, D ;

Bourmpoulia, D ;

Ledermann, J ;

Boshoff, C .

BRITISH JOURNAL OF CANCER, 2004, 90 (03) :686-692

[2] The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma [J].

Banelli, Barbara ;

Carra, Elisa ;

Barbieri, Federica ;

Wuerth, Roberto ;

Parodi, Federica ;

Pattarozzi, Alessandra ;

Carosio, Roberta ;

Forlani, Alessandra ;

Allemanni, Giorgio ;

Marubbi, Daniela ;

Florio, Tullio ;

Daga, Antonio ;

Romani, Massimo .

CELL CYCLE, 2015, 14 (21) :3418-3429

[3] Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling [J].

Bashashati, Ali ;

Ha, Gavin ;

Tone, Alicia ;

Ding, Jiarui ;

Prentice, Leah M. ;

Roth, Andrew ;

Rosner, Jamie ;

Shumansky, Karey ;

Kalloger, Steve ;

Senz, Janine ;

Yang, Winnie ;

McConechy, Melissa ;

Melnyk, Nataliya ;

Anglesio, Michael ;

Luk, Margaret T. Y. ;

Tse, Kane ;

Zeng, Thomas ;

Moore, Richard ;

Zhao, Yongjun ;

Marra, Marco A. ;

Gilks, Blake ;

Yip, Stephen ;

Huntsman, David G. ;

McAlpine, Jessica N. ;

Shah, Sohrab P. .

JOURNAL OF PATHOLOGY, 2013, 231 (01) :21-34

[4] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[5] Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells [J].

Bhattacharya, Rahul ;

Mitra, Tulika ;

Chaudhuri, Susri Ray ;

Roy, Sib Sankar .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (04) :3373-3383

[6] First-line Chemotherapy in Epithelial Ovarian Cancer [J].

Bookman, Michael A. .

CLINICAL OBSTETRICS AND GYNECOLOGY, 2012, 55 (01) :96-113

[7]

Brown TM, 2006, AM J PUBLIC HEALTH, V96, P2104, DOI 10.2105/AJPH.2005.078436

[8] Tumour heterogeneity and the evolution of polyclonal drug resistance [J].

Burrell, Rebecca A. ;

Swanton, Charles .

MOLECULAR ONCOLOGY, 2014, 8 (06) :1095-1111

[9] BRCA-mutation-associated fallopian tube carcinoma - A distinct clinical phenotype? [J].

Cass, R ;

Holschneider, C ;

Datta, N ;

Barbuto, D ;

Walts, AE ;

Karlan, BY .

OBSTETRICS AND GYNECOLOGY, 2005, 106 (06) :1327-1334

[10] Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease [J].

Castellarin, Mauro ;

Milne, Katy ;

Zeng, Thomas ;

Tse, Kane ;

Mayo, Michael ;

Zhao, Yongjun ;

Webb, John R. ;

Watson, Peter H. ;

Nelson, Brad H. ;

Holt, Robert A. .

JOURNAL OF PATHOLOGY, 2013, 229 (04) :515-524

← 1 2 3 4 5 6 7 8 9 10 →